Iron Deficiency Anemia Therapeutics
1. Accrufer patent expiration
Treatment: Method of treating iron deficiency
ACCRUFER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9802973 | SHIELD TX | Crystalline forms of ferric maltol |
Oct, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10179120 | SHIELD TX | Dosage regimen of ferric trimaltol |
Jan, 2035
(8 years from now) | |
| US9248148 | SHIELD TX | Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2024 |
Drugs and Companies using FERRIC MALTOL ingredient
NCE-1 date: 26 July, 2023
Market Authorisation Date: 25 July, 2019
Dosage: CAPSULE
More Information on Dosage
ACCRUFER family patents
